Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation

Drugs

Volumn 72, Issue SUPPL. 1, 2012, Pages 3-10

  Mok, Tony S K ^a   D'Arcangelo, Manolo ^b   Califano, Raffaele ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO;

ASIAN; CANCER CHEMOTHERAPY; CANCER PATIENT; CHINA; DISEASE CONTROL; EUROPE; GENE MUTATION; HAZARD RATIO; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MUTATION; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862580343     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/1163014-S0-000000000-00000     Document Type: Review

References (50)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39 (Pubitemid 38637993)
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500 (Pubitemid 38720929)
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57
4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previsouly treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366 (9464): 1527-37 (Pubitemid 41540110)
5. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Ins 2005; 97: 339-46 (Pubitemid 40425952)
6. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817-24 (Pubitemid 350002184)
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al., National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-32 (Pubitemid 41058344)
8. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erltotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4286-75
9. Zhou C, Wu Y-L, Chen G, et al. OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann Oncol 2010; 21 Suppl. 8: viii6 (Abstract LBA13)
10. Mok T, Wu YL, Au JS, et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian Patients with advanced non-small-cell lung cancer. J Thoracic Oncol 2010; 5 (10): 1609-15
11. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361 (10): 958-67
12. Gervais R, Rosell R, Vergnenegre A, et al. The EURTAC (European Tarceva vs Chemotherapy) study: Interim results of a phase III randomized trial of erlotinib vs chemotherapy in advanced non-small-cell lung cancer patients with epidermal growth factor receptor activating mutations. J Thor Oncol 2011; 6 Suppl. 6: S314
13. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker Analyses and Final Overall Survival Results from a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients with Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). J Clin Oncol 2011, 29 (21): 2866-74
14. Lee JS, Park K, KimSW, et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. 13th World Conference on Lung Cancer; 2009; San Francisco, CA, USA
15. Mitsudomi T, Morita S, Yatabe Y, et al., West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8
16. Maemondo M, Inoue A, Kobayashi K, et al., North-East Japan Study Group. Gefitinib or chemotherapy for non-small- cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8
17. Rosell R, Carcerney F, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small- cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology 2012; 13 (2): 239-46
18. Paz-Ares L, Soulières D, Melezínek I, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010; 14 (1-2): 51-69
19. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-84 (Pubitemid 41103588)
20. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-94 (Pubitemid 41103589)
21. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-9
22. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-52 (Pubitemid 46733081)
23. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23 (25): 5900-9
24. Janne PA, Wang XF, Socinski MA, et al. Randomized phase II trial of erlotinib alone or in combination with carbo-platin/ paclitaxel in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. ASCO MEETING ABSTRACTS Jun 14, 2010: 7503
25. Piperdi B, Ling Y, Kroog G, et al. Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro. J Clin Oncol 2004; 23: 620, (suppl; abstr 7028)
26. Davies AM, Ho C, Lara Jr PN, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 385-8 (Pubitemid 44043547)
27. Li T, Ling Y-H, Goldman I, et al. Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells. Clin Cancer Res 2007; 13: 3413-22 (Pubitemid 46944930)
28. Davies AM, Hesketh PJ, Beckett L, et al. Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism. J Clin Oncol 2007; 25: 413s, (suppl; abstr 7618)
29. Davies AM, Ho C, Beckett L, et al. Intermittent erlotinib (ERL) in combination with pemetrexed (PEM): Phase I schedules designed to achieve pharmacodynamic separation. J Clin Oncol 2008; 26: 1431s, (suppl; abstr 8032)
30. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11 (6): 521-9
31. Meany HJ, Fox E, McCully C, et al. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Cancer Chemother Pharmacol 2008; 62 (3): 387-92 (Pubitemid 351871796)
32. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007; 13 (5): 1511-15 (Pubitemid 46450442)
33. Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J ThoracOncol 2010; 5 (7): 950-5
34. Raizer JJ, Abrey LE, Lassman AB, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 2010; 12 (1): 95-103
35. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005; 11 (21): 7841-50 (Pubitemid 41611629)
36. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57 (21): 4838-48 (Pubitemid 27468992)
37. Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009; 65 (3): 351-4
38. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009; 4 (11): 1415-19
39. Porta R, Sánchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 37 (3): 624-31
40. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-302 (Pubitemid 35266289)
41. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor kinase inhibitor, in patients withadvanced solid malignancies. J Clin Oncol 2011; 19 (13): 3267-79
42. Cho BC, Im C, Park M, et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007; 25 (18): 2528-33 (Pubitemid 47041225)
43. Vasile E, Tibaldi C, Falcone A. Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients? Ann Oncol 2009; 20 (4): 790-1
44. Lee DH, Kim S-W, Suh C, et al. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008 Jul; 19: 2039-42
45. Kaira K, Naito T, Takahashi T, et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small-cell lung cancer. Lung Cancer 2010; 68 (1): 99-104
46. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 768-92
47. Engelman JA, Zejnullah K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43 (Pubitemid 46799492)
48. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007; 13 (17): 5150-5 (Pubitemid 47502083)
49. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010 10; 28 (2): 357-60
50. Mok TSK. Personalized medicine in lung cancer: What we need to know. Nat Rev Clin Oncol 8 (11): 661-8